Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Adenocarcinoma: early-phase trial registry
31 of 63 indexed Pancreatic Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #222 of 28,707 conditions by registered trial count.
63 US clinical trials · 31 currently recruiting · #222 of 28,707 conditions by registered trial count
Pancreatic Adenocarcinoma: 63 US clinical trials tracked, 31 recruiting.
Pancreatic Adenocarcinoma is the subject of 63 registered US clinical trials on ClinicalTrials.gov, 31 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 46 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition pancreatic-adenocarcinoma
OPEN 31 | RECR 49% | LATE 1 | EARLY 46 | RANK #222 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Anxiety Disorders (49% recruiting · 85 trials)
Pancreatic Adenocarcinoma lists 31 open slots (49% of 63 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Adenocarcinoma is recruiting above its size-band peers.
31 of 63 indexed trials (49.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Adenocarcinoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 4 of 63 trials (6.3%). 53 distinct sponsors appear on at least one study for this condition label.
-
Typical Pancreatic Adenocarcinoma enrolment sits around 66 participants.
Median target enrolment is 66 among the 63 trials that report a genuine target (sentinel values excluded). 37 of those (58.7%) plan for fewer than 100 participants.
-
Pancreatic Adenocarcinoma research is mostly interventional.
53 interventional and 10 observational studies make up this index (84.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
63 total, page 2 of 2
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
Corewell Health West
NCT03856658
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
NCT06115499
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT04137536
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT05451849
Spectroscopy From Duodenum
Olympus Corporation
NCT01753479
Assessment of What Patients and Healthcare Providers Value
M.D. Anderson Cancer Center
NCT04483349
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Theriva Biologics SL
NCT05673811
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
AmpliMed Corporation
NCT00327327
Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT01474564
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Academic Thoracic Oncology Medical Investigators Consortium
NCT02723331
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00288093
Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis
AdventHealth
NCT03152487
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
NCT05795595
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 15 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Adenocarcinoma page
63 registered trials, 31 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 31 Pancreatic Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Pancreatic Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Adenocarcinoma condition card totals 63 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.